Background: Impaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The purpose of the present study was to examine whether pioglitazone (ACTOS) can prevent progression of IGT to type 2 diabetes mellitus (T2DM) in a prospective randomized, double blind, placebo controlled trial.
Methods/design: 602 IGT subjects were identified with OGTT (2-hour plasma glucose = 140-199 mg/dl). In addition, IGT subjects were required to have FPG = 95-125 mg/dl and at least one other high risk characteristic. Prior to randomization all subjects had measurement of ankle-arm blood pressure, systolic/diastolic blood pressure, HbA1C, lipid profile and a subset had frequently sampled intravenous glucose tolerance test (FSIVGTT), DEXA, and ultrasound determination of carotid intima-media thickness (IMT). Following this, subjects were randomized to receive pioglitazone (45 mg/day) or placebo, and returned every 2-3 months for FPG determination and annually for OGTT. Repeat carotid IMT measurement was performed at 18 months and study end. Recruitment took place over 24 months, and subjects were followed for an additional 24 months. At study end (48 months) or at time of diagnosis of diabetes the OGTT, FSIVGTT, DEXA, carotid IMT, and all other measurements were repeated.Primary endpoint is conversion of IGT to T2DM based upon FPG >or= 126 or 2-hour PG >or= 200 mg/dl. Secondary endpoints include whether pioglitazone can: (i) improve glycemic control (ii) enhance insulin sensitivity, (iii) augment beta cell function, (iv) improve risk factors for cardiovascular disease, (v) cause regression/slow progression of carotid IMT, (vi) revert newly diagnosed diabetes to normal glucose tolerance.
Conclusion: ACT NOW is designed to determine if pioglitazone can prevent/delay progression to diabetes in high risk IGT subjects, and to define the mechanisms (improved insulin sensitivity and/or enhanced beta cell function) via which pioglitazone exerts its beneficial effect on glucose metabolism to prevent/delay onset of T2DM.
Trial Registration: clinical trials.gov identifier: NCT00220961.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725044 | PMC |
| http://dx.doi.org/10.1186/1472-6823-9-17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential effect of nonpharmacological interventions according to prediabetes phenotype: Systematic review and meta-analysis of randomized clinical trials.
Diabet Med
January 2025
Universidad Científica del Sur, Lima, Peru.
Background And Aims: Impaired glucose intolerance (IGT) and impaired fasting glucose (IFG) are totally different. Lifestyle modification is effective in moving from prediabetes to normoglycaemia. There is a lack of information showing the effect of lifestyle modification according to each prediabetes and assessing its effect on the degree of reversibility to normoglycaemia and on cardiometabolic markers.
View Article and Find Full Text PDFNutraceuticals and Supplements in Management of Prediabetes and Diabetes.
Nutrients
December 2024
SINut-Società Italiana di Nutraceutica, Via Guelfa, 9, 40138 Bologna, Italy.
Dysglycemia is a condition preceding diabetes mellitus. The two situations inherent in this condition are called impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). If one of these situations is found in the patient, after the advice of an appropriate diet and physical activity, the addition of nutraceuticals or supplements can be considered, which can stop or delay the progression to diabetes mellitus over time.
View Article and Find Full Text PDFAbnormal glucagon secretion contributes to a longitudinal decline in glucose tolerance.
J Clin Endocrinol Metab
January 2025
Division of Endocrinology, Diabetes & Metabolism, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Context: Defects in insulin secretion and action contribute to the progression of prediabetes to diabetes. However, the contribution of α-cell dysfunction to this process has been unclear.
Objective: Understand the relative contributions of α-cell and β-cell dysfunction to declining glucose tolerance.
The effect of transcranial Direct Current Stimulation on the Iowa Gambling Task: a scoping review.
Front Psychol
December 2024
Department of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy.
Article Synopsis
- The Iowa Gambling Task (IGT) is an effective method for studying decision-making processes by providing feedback on choices, and its study has recently incorporated transcranial direct current stimulation (tDCS) to explore cognitive and neural mechanisms.
- A scoping review found that tDCS could improve IGT performance, particularly highlighting the importance of the dorsolateral prefrontal cortex and orbitofrontal cortex in making risky or ambiguous decisions.
- The findings suggest that tDCS can enhance decision-making in both healthy individuals and patients, indicating its potential application in daily decisions and emphasizing the need for further research into the underlying mechanisms.
Beta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance.
BMJ Open Diabetes Res Care
December 2024
Department of Endocrinology, Medical University-Sofia, Sofia, Bulgaria.
Introduction: Previous studies have suggested an association between beta-cell and autonomic function and metabolic-associated fatty liver disease (MAFLD). We explored the association between controlled attenuated parameter (CAP) and insulin secretion and action, as well as sympathetic and parasympathetic activity in normal (NGT) and impaired (IGT) glucose tolerance.
Research Design And Methods: Twenty-five NGT (age 44.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!